Skip to main content

Advertisement

Table 2 Minor reported AEs from reviewed studies

From: Fish oil administration in older adults: is there potential for adverse events? A systematic review of the literature

Minor AEs Authors Fish oil Placebo
GI disturbances Rondanelli et al. 2010 [40] 6/22 (27.3%) 5/22 (22.7%)
  Van de Rest et al. 2009 [3639]a High dose: 10/96 (10.4%) 12/106 (11.3%)
   Low dose: 9/100 (9%)  
  Thies et al. 2001 [31, 32] 1/8 (12.5%) -
  Fakhrzadeh et al. 2010 [43] 2/62 (3%) 1/62 (1.5%)
  Holguin et al. 2005 [44] 14/26 (53.8%) 6/26 (23.1%)
Headache Rondanelli et al. 2010 [40] - 1/24 (4%)
Skin irritation Gruenwald et al. 2009 [42] 2/90 (2%) -
  Van de Rest et al. 2009 [3235]a - 1/106 (0.9%)
Vertigo Fakhrzadeh et al. 2010 [43] 1/62 (1.5%) -
Malaise Fakhrzadeh et al. 2010 [43] 1/62 (1.5%) -
  Van de Rest et al. 2009 [3235]a Low dose: 1/100 (1%) -
Weight gain Van de Rest et al. 2009 [3235]a High dose: 1/96 (1%) -
Polyurination Van de Rest et al. 2009 [3235]a High dose: 1/96 (1%) -
Restlessness Van de Rest et al. 2009 [3235]a High dose: 1/96 (1%) -
Blurred vision Van de Rest et al. 2009 [3235]a Low dose: 1/100 (1%) 1/106 (0.9%)
Sore throat Van de Rest et al. 2009 [3235]a Low dose: 1/100 (1%) -
Skeletal muscle pain Van de Rest et al. 2009 [3235]a Low dose: 1/100 (1%) 1/106 (0.9%)
  1. a Investigators from Van de Rest et al. 2009 [3639] included 2 intervention doses of n-3 fish oil; high dose: 1.8 g/d EPA/DHA; low dose: 0.4 g/d EPA/DHA.